The impact of these drugs has also been examined specifically in AF populations, with some, particularly studies of SGLT2 inhibitors, indicating reduced risks of outcomes such as AF-related hospitalizations, stroke and ventricular arrhythmias in addition to death and HF hospitalizations [36,37,38,39,40]. The gene discussed is SLC5A2; the disease is atrial fibrillation.